Top Ranked Value Stocks to Buy for October 29th

Here are three stocks with buy rank and strong value characteristics for investors to consider today, October 29th:

Pampa Energia S.A. (PAM): This integrated electricity company has a Zacks Rank #2, and seen the Zacks Consensus Estimate for its current year earnings rising 32.8% over the last 90 days.

Pampa Energia S.A. Price and Consensus

Pampa Energia S.A. price-consensus-chart | Pampa Energia S.A. Quote

Pampa Energia has a price-to-earnings ratio (P/E) of 3.5, compared with 17.6 for the industry. The company possesses a Value Score of A.

Pampa Energia S.A. PE Ratio (TTM)

Pampa Energia S.A. pe-ratio-ttm | Pampa Energia S.A. Quote

Sappi Limited (SPPJY): This woodfibre company has a Zacks Rank #2, and seen the Zacks Consensus Estimate for its next year earnings rising 4.6% over the last 60 days.

Sappi Ltd. Price and Consensus

Sappi Ltd. price-consensus-chart | Sappi Ltd. Quote

Sappi has a price-to-earnings ratio (P/E) of 4.04, compared with 10.3 for the industry. The company possesses a Value Score of A.

Sappi Ltd. PE Ratio (TTM)

Sappi Ltd. pe-ratio-ttm | Sappi Ltd. Quote

Jounce Therapeutics, Inc. (JNCE): This clinical-stage immunotherapy company has a Zacks Rank #2, and seen the Zacks Consensus Estimate for its current year earnings rising more than 100% over the last 90 days.

Jounce Therapeutics, Inc. Price and Consensus

Jounce Therapeutics, Inc. price-consensus-chart | Jounce Therapeutics, Inc. Quote

Jounce Therapeutics has a price-to-earnings ratio (P/E) of 2.32, compared with 9 for the industry. The company possesses a Value Score of B.

Jounce Therapeutics, Inc. PE Ratio (TTM)

Jounce Therapeutics, Inc. pe-ratio-ttm | Jounce Therapeutics, Inc. Quote

See the full list of top ranked stocks here.

Learn more about the Value score and how it is calculated here.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.